title: Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
abstract: Ceftobiprole is a novel broad-spectrum cephalosporin that binds with high affinity to PBP 2a, the methicillin-resistance determinant of staphylococci, and is active against methicillin- and vancomycin-resistant Staphylococcus aureus. Ceftobiprole was compared to vancomycin in a rabbit model of methicillin-resistant S. aureus aortic valve endocarditis. Ceftobiprole and vancomycin were equally effective against endocarditis caused by methicillin-resistant S. aureus strain 76, whereas ceftobiprole was more effective than vancomycin against the vancomycin-intermediate S. aureus strain HIP5836. The activity of ceftobiprole against drug-resistant strains of S. aureus warrants its further clinical development.
authors.affiliation: Division of Infectious Diseases, San Francisco General Hospital, and University of California--San Francisco, Room 3400, Building 30, 1001 Potrero Ave., San Francisco, CA 94110, USA. chipc@itsa.ucsf.edu
authors.forename: Henry F
authors.initials: HF
authors.lastname: Chambers
mesh_terms: D000818:Animals; D001021:Aortic Valve; D002511:Cephalosporins / Q000097:blood / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D006349:Heart Valve Diseases / Q000188:drug therapy*; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000097:blood / Q000627:therapeutic use*
chemical_list: D002511:Cephalosporins; C443755:ceftobiprole; D014640:Vancomycin
references.citation: Antimicrob Agents Chemother. 2002 Jan;46(1):171-7
references.pmid: 11751129
references.citation: Antimicrob Agents Chemother. 2000 Feb;44(2):272-7
references.pmid: 10639349
references.citation: Antimicrob Agents Chemother. 2002 Apr;46(4):971-6
references.pmid: 11897577
references.citation: Nat Struct Biol. 2002 Nov;9(11):870-6
references.pmid: 12389036
references.citation: J Antimicrob Chemother. 2003 Nov;52(5):864-8
references.pmid: 14563898
references.citation: Antimicrob Agents Chemother. 2004 Feb;48(2):453-9
references.pmid: 14742194
references.citation: Antimicrob Agents Chemother. 2001 Mar;45(3):825-36
references.pmid: 11181368
references.citation: Antimicrob Agents Chemother. 2004 Apr;48(4):1105-11
references.pmid: 15047508
references.citation: Antimicrob Agents Chemother. 2004 Jul;48(7):2570-5
references.pmid: 15215110
references.citation: Antimicrob Agents Chemother. 2004 Jul;48(7):2576-80
references.pmid: 15215111
references.citation: Antimicrob Agents Chemother. 2004 Jul;48(7):2719-23
references.pmid: 15215134
references.citation: J Infect Dis. 1990 Sep;162(3):705-10
references.pmid: 2387996
references.citation: J Infect Dis. 1995 Apr;171(4):897-902
references.pmid: 7706817
references.citation: Antimicrob Agents Chemother. 1995 Feb;39(2):462-6
references.pmid: 7726516
references.citation: Antimicrob Agents Chemother. 1995 Apr;39(4):910-6
references.pmid: 7785994
references.citation: J Clin Microbiol. 1998 Apr;36(4):1020-7
references.pmid: 9542929
references.citation: Bioorg Med Chem. 1998 Jul;6(7):1089-101
references.pmid: 9730246
references.citation: Antimicrob Agents Chemother. 1999 Jul;43(7):1747-53
references.pmid: 10390234
references.citation: Antimicrob Agents Chemother. 2002 Feb;46(2):321-6
references.pmid: 11796337